Esophageal squamous cell carcinoma (ESCC), the most predominant subtype of esophageal cancer, is notorious for its high lymph node metastatic potential and poor prognosis. Growing evidence has demonstrated crucial function of circRNAs in human malignancies. However, the knowledge of circRNAs in lymph node metastasis of ESCC is still inadequate. In this study, a series of bioinformatic analyses and experimental validation were performed. By performing differential expression analysis and selection for GEO dataset GSE150476, a total of 8 circRNAs associated with lymph node metastasis of ESCC were identified. Expression analysis confirmed their low expression in ESCC tissues (relative to normal tissues) or metastatic sites (relative to primary sites). By combination of binding miRNAs from CSCD and starBase databases, six potential miRNAs (miR-532-5p, miR-2681-5p, miR-670-5p, miR-1252-5p, miR-382-3p and miR-542-3p) were predicted and a circRNA-miRNA regulatory network was constructed. Next, 695 target genes were predicted to bind to the 6 miRNAs. After conducting protein-protein interaction (PPI) network analysis, hub gene identification and expression analysis, a hub gene PIK3R1 was identified as the most potential downstream target gene of hsa_circ_0087104/miR-542-3p in ESCC. Hsa_circ_0087104 and PIK3R1 were decreased while miR-542-3p was increased in ESCC cells compared with normal esophageal epithelial cell line. Luciferase reporter and MS2-RIP assays confirmed the direct bind of miR-542-3p to hsa_circ_0087104 or PIK3R1. Hsa_circ_0087104 increased PIK3R1 expression but ectopic expression of miR-542-3p reversed hsa_circ_0087104-mediated PIK3R1 overexpression in ESCC. Overexpression of hsa_circ_0087104 suppressed migration and invasion of ESCC cells and this suppressive effect could be weakened by upregulation of miR-542-3p. Collectively, the current findings elucidated a potential hsa_circ_0087104/miR-542-3p/PIK3R1 axis that might be involved in suppression of lymph node metastasis of ESCC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711534 | PMC |
http://dx.doi.org/10.62347/EFEO7205 | DOI Listing |
Clin Cancer Res
January 2025
Mater Research Institute - University of Queensland, Woolloongabba, Qld, Australia.
Purpose: Receptor CUB-domain containing- protein 1 (CDCP1) was evaluated as a target for detection and treatment of breast cancer.
Experimental Design: CDCP1 expression was assessed immunohistochemically in tumors from 423 patients (119 triple-negative breast cancer (TNBC); 75 HER2+; 229 ER+/HER2- including 228 primary tumors, 229 lymph node and 47 distant metastases). Cell cytotoxicity induced in vitro by a CDCP1-targeting antibody-drug conjugate (ADC), consisting of the human/mouse chimeric antibody ch10D7 and the microtubule disruptor monomethyl auristatin E (MMAE), was quantified, including in combination with HER2-targeting ADC T-DM1.
Dermatitis
January 2025
From the Department of Allergy and Clinical Immunology, Unidade Local de Saúde de São João, Porto, Portugal.
Patent Blue V (PBV) is extensively used in sentinel lymph node identification in cancer surgery, potentially leading to an increased incidence of hypersensitivity reactions. A retrospective analysis was conducted on patients with suspected PBV hypersensitivity, at our center from 2010 to 2023. Skin prick tests (SPT) were performed on all patients, followed by intradermal tests (IDT) if SPT was negative.
View Article and Find Full Text PDFInt J Gynecol Pathol
January 2025
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Faculty of Medicine, Muğla Sitki Koçman University, Muğla, Turkey.
This study aims to investigate the expression pattern of human chorionic gonadotropin (hCG) in the tissue of endometrioid type endometrial cancer (EEC) using immunohistochemistry, and also to investigate the effect of hCG expression pattern on prognosis and survival in EEC. We evaluated patients who were operated between 2010 and 2020 in the obstetrics and gynecology clinic of our center due to EEC. In total, 194 women were determined to be in either the hCG-negative group (n=137) or the hCG-positive group (n=57).
View Article and Find Full Text PDFLymphat Res Biol
January 2025
Department of Plastic and Reconstructive Surgery, Medical Centre of Postgraduate Education, Warsaw, Poland.
Upper limb lymphedema is the most common complication after breast cancer therapy. Suddenly disturbed lymphatic transport in the affected arm causes tissue fluid accumulation in tissue spaces, limb enlargement, and secondary changes in tissue. Early compression therapy is necessary.
View Article and Find Full Text PDFCurr Opin Oncol
January 2025
Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB).
Purpose Of Review: This review aims to explore the evolving management strategies for stage III melanoma, focusing on the comparative effectiveness of traditional surgical approaches like complete lymph node dissection (CLND) versus modern adjuvant therapies. It also examines the latest evidence on the efficacy, risks, and complications of these strategies, emphasizing the role of shared decision-making between patients and clinicians.
Recent Findings: Recent clinical trials and meta-analyses, including the MSLT-II and DeCOG-SLT studies, have demonstrated that CLND may not significantly improve survival outcomes in melanoma patients with sentinel lymph node biopsy (SLNB)-positive status.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!